These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 9062138

  • 1. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
    Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, Curiel DT.
    Gynecol Oncol; 1997 Mar; 64(3):378-85. PubMed ID: 9062138
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT.
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
    Grim J, Deshane J, Feng M, Lieber A, Kay M, Curiel DT.
    Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
    [Abstract] [Full Text] [Related]

  • 7. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
    Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.
    J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT.
    Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
    [Abstract] [Full Text] [Related]

  • 11. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model.
    Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC.
    Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307
    [Abstract] [Full Text] [Related]

  • 12. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer.
    Arafat WO, Gómez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD, Siegal GP, Badib AO, Buchsbaum D, Curiel DT, Stackhouse MA.
    Mol Ther; 2000 Jun; 1(6):545-54. PubMed ID: 10933979
    [Abstract] [Full Text] [Related]

  • 13. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
    Rancourt C, Bergeron C, Lane D, Garon G, Piché A.
    Cytotherapy; 2003 Jun; 5(6):509-22. PubMed ID: 14660047
    [Abstract] [Full Text] [Related]

  • 14. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
    Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, Esposito G, Wagner R, Uberla K, Chieco-Bianchi L, Amadori A.
    Cancer Res; 2002 Nov 01; 62(21):6099-107. PubMed ID: 12414634
    [Abstract] [Full Text] [Related]

  • 15. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M.
    Cancer Gene Ther; 2002 Jul 01; 9(7):553-66. PubMed ID: 12082455
    [Abstract] [Full Text] [Related]

  • 16. Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth.
    Palmer K, Sharan N, Emtage P, Gauldie J, Muller WJ, Wan Y.
    Gene Ther; 2002 Jul 01; 9(13):898-905. PubMed ID: 12080384
    [Abstract] [Full Text] [Related]

  • 17. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 10; 82(17):1207-10. PubMed ID: 12475412
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
    Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT.
    Clin Cancer Res; 2001 Jul 10; 7(7):2057-66. PubMed ID: 11448924
    [Abstract] [Full Text] [Related]

  • 20. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
    Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT.
    Gene Ther; 2002 Feb 10; 9(4):256-62. PubMed ID: 11896464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.